suPAR can preditct Chronic Kidney Disease according to new data in New England Journal of Medicine
A new study in the New England Journal of Medicine shows that suPAR reliably can predict the development of Chronic Kidney Disease up to five years before symptoms of this disease emerge - a disease that affects an estimated 600 million people.
Currently, physicians rely on two markers to monitor existing kidney disease, but they are not sensitive enough to predict a persons risk of developing the disease or to catch it in its early stages.
The New England Journal of Medicine study found that a high suPAR level was an excellent predictor of future kidney disease and a significant breakthrough in preventive medicine.
Results are based upon research using the suPARnostic® products from ViroGates.
Jakob Knudsen, CEO of ViroGates comments: " We are pleased that our products can help to identify patients in risk of developing chronic kidney disease earlier than what has been possible to date, and we look forward to help the medical community use these results in clinical practice".